Viridian Therapeutics, Inc./DE Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price
Viridian Therapeutics, Inc./DE (VRDN) had Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price of $16.82 per share as of 2025-12-31, per its 10-K filed 2026-02-26.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice · last filed 2026-02-26
- 2025-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $16.82.
- 2024-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $18.11.
- 2016-12-31: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $28.83.
- 2016-09-30: Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price $1.93.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price | Share-based Compensation Arrangement by Share-based Payment Award, Options, Outstanding, Weighted Average Exercise Price as first filed |
|---|---|---|
| 2025-12-31 | $16.82 10-K · filed 2026-02-26 | |
| 2024-12-31 | $18.11 10-K · filed 2026-02-26 | |
| 2016-12-31 | $28.83 10-K · filed 2017-03-24 | |
| 2016-09-30 | $1.93 10-Q · filed 2016-10-26 | |
| 2016-06-30 | $1.94 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $2.18 10-Q · filed 2016-05-16 | |
| 2015-12-31 | $34.20 10-K · filed 2017-03-24 | $2.28 10-K · filed 2016-03-21 |
| 2015-09-30 | $2.27 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $4.17 10-Q · filed 2015-08-14 | |
| 2015-03-31 | $4.19 10-Q · filed 2015-05-15 | |
| 2014-12-31 | $4.53 10-K · filed 2016-03-21 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |